Growth inhibitory effect of the antibody to hematopoietic stem cell antigen CD34 in leukemic cell lines

Neoplasma

Volumn 54, Issue 4, 2007, Pages 311-320

  Elknerova K ^a   Lacinova Z ^a   Soucek J ^a   Marinov, I ^a   Stockbauer P ^a  

^a INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

Author keywords

Apoptosis; CD34 antigen; Cellular senescence; Leukemia cell lines; Monoclonal antibody therapy; Proliferation

Indexed keywords

CD34 ANTIGEN; MONOCLONAL ANTIBODY;

APOPTOSIS; ARTICLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; GROWTH INHIBITION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; LEUKEMIA CELL; CELL CULTURE; CELL CYCLE; IMMUNOLOGY; LEUKEMIA; METABOLISM; PHYSIOLOGY;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD34; APOPTOSIS; CELL CYCLE; CELL PROLIFERATION; CELLS, CULTURED; HEMATOPOIETIC STEM CELLS; LEUKEMIA;

EID: 35448965205     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. MILLER RA, MALONEY DG, WARNKE R, LEVY R. Treatment of B-cell lymphoma with monoclonal anti-idio-type antibody. N Engl J Med 1982, 306: 517-522.
2. MILLER RA, LEVY R. Response of cutaneous T cell lymphoma monoclonal antibody. Lancet 1981, 2: 226-230.
3. PRESS OW, APPELBAUM F, LEDDBETTER JA. Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. Blood 1987, 69: 584-591.
4. TSUJI-TAKAYAMA K. Establishment of multiple leukemia cell lines with diverse myeloid and/or megakaryoblastoid characteristics from a single Ph1 positive chronic myelogenous leukemia blood sample. Hum Cell 1994, 7: 167-171.
5. DI NOTO R, LUCIANO L, LO PARDO C et al. JURL-MK1 (c-kit(high)/CD30-/CD40- ) and JURL-MK2 (c-kit(low)/CD30+/ CD40+) cell lines: 'two-sided' model for investigating leukemic megakaryocytopoiesis. Leukemia 1997, 11: 1554-1564.
6. STÖCKBAUER P, HRADCOVÁ M, NOVÁK JT et al. Monoclonal antibody to a human chronic myeloid leukaemia cell line reacts with antigen in apoptotic cells and apoptotic bodies. In: MASON D editor. Leukocyte typing VII. New York: Oxford University Press, 2002: 63-68.
7. DICK JE. Breast cancer stem cells revealed. P Natl Acad Sci USA 2003, 100: 3547-3549.
8. REYA T, MORRISON SJ, CLARKE MF, WEISSMAN IL. Stem cells, cancer stem cells. Nature 2001, 414: 105-111.
9. WANG JCY, DICK JE. Cancer stem cells: lessons from leukemia. Trends Cell Biol 2005, 15: 494-501.
10. LAPIDOT T, SIRARD C, VORMOOR J et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994, 367: 645-648
11. BONNET D, DICK JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997, 3: 730-737.
12. JAMIESON CH, AILLES LE, DYLLA SJ. Granulocyte macrofage progenitors as candidate leukemic stem cells in blast crisis CML. N Engl J Med 2004, 351: 657-667.
13. BLAIR A, HOGGE DE, AILLES LE et al. Lack of expression of Thy-1 (CD90) on acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo. Blood 1997, 89: 3104-3112.
14. BLAIR A, SUTHERLAND HJ. Primitive acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo lack surface expression of c-kit (CD117). Exp Hematol 2000, 28: 660-671.
15. JORDAN CT, UPCHURCH D, SZILVASSY SJ et al. The interleukin-3 recepror alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia 2000, 14: 1777-1784.
16. ZADA AAP, SINGH SM, REDDY VA et al. Down regulation of c-jun expression and cell cycle regulatory molecules in acute myeloid leukemia cells upon CD44 ligation. Oncogene 2003, 22: 2296-2308.
17. CHARRAD RS, GADHOUM Z, QI J, GLACHANT A et al. Effect of anti-CD44 monoclonal antibodies on differentiation and apoptosis of human myeloid leukemia cell lines. Blood 2002, 99: 290-299.
18. CESANO A, PIERSON G, VISONNEAU S et al. Use of a lethally irradiated major histocompability complex nonrestricted cytotoxic T-cell line for effective purging of marrows containing lysis-sensitive or - resistant leukemic targets. Blood 1996, 87: 393-403.
19. BORDEN EC. Review: Milstein Award lecture: interferons and cancer: where from here? J Interferon Cytokine Res 2005, 25: 511-527.
20. ALLAN NC, RICHARDS SM, SHEPHERD PC. UK Medical research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukaemia. Lancet 1995, 345:1392-1397.
21. JAHAGINDAR BN, MILLER JS, SHET A, VERTAILLE CM. Novel therapies for chronic myelogenous leukemia. Exp Hematol 2001, 29: 543-556.
22. BENJAMIN R, KHWAJA A, SINGH N et al. Continuous delivery of human type I interferons (α/β) has significant activity against acute myeloid leukemia cells in vitro and in a xenograft model. Blood 2006, (in press).
23. PERUSSIA B, DAYTON ET, FANNING V et al. Immune interferon and leukocyte-conditioned medium induce normal and leukemic myeloid cells to differentiate along the monocytic pathway. J Exp Med 1983, 158:2058-2080.